ULTRAVAC 5 IN 1 VACCINE

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

Buy It Now

Active ingredient:
CLOSTRIDIUM CHAUVOEI - FORMOL CULTURE; CLOSTRIDIUM NOVYI TYPE B; CLOSTRIDIUM PERFRINGENS TYPE D TOXOID; CLOSTRIDIUM SEPTICUM - TOXOID; TETANUS = CLOSTRIDIUM TETANI; THIOMERSAL
Available from:
ZOETIS AUSTRALIA PTY LTD
INN (International Name):
Cl perfringens toxoid (D)+Cl tetani - toxoid+Cl novyi type B + others
Pharmaceutical form:
MISC. VACCINES OR ANTI SERA
Composition:
CLOSTRIDIUM CHAUVOEI - FORMOL CULTURE VACCINE-MICROBIAL Active 0.0 P; CLOSTRIDIUM NOVYI TYPE B VACCINE-MICROBIAL Active 0.0 P; CLOSTRIDIUM PERFRINGENS TYPE D TOXOID VACCINE-TOXOID Active 0.0 P; CLOSTRIDIUM SEPTICUM - TOXOID VACCINE-TOXOID Active 0.0 P; TETANUS = CLOSTRIDIUM TETANI VACCINE-TOXOID Active 0.0 P; THIOMERSAL MERCURY Other 0.1 mg/ml
Units in package:
100mL; 250mL; 500mL; 50mL
Class:
VM - Veterinary Medicine
Manufactured by:
ZOETIS AUSTRALIA
Therapeutic group:
CATTLE | SHEEP | SHEEP RAM (MALE) | BEEF | BOS INDICUS | BOS TAURUS | BOVINE | BUFFALO | BULL | BULLOCK | CALF | COW | DAIRY COW
Therapeutic area:
IMMUNOTHERAPY
Therapeutic indications:
BLACK DISEASE | BLACKLEG | ENTEROTOXAEMIA (PULPY KIDNEY) | MALIGNANT OEDEMA | SWELLED HEAD | TETANUS | VACCINE | CLOSTRIDIUM PERFRINGENS TYPE D | EQUINE ROTAVIRUS | TETANUS VACCINATION
Product summary:
Poison schedule: 0; Withholding period: WHP: NIL; Host/pest details: CATTLE: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, VACCINE]; SHEEP: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, VACCINE]; SHEEP RAM (MALE): [SWELLED HEAD]; Poison schedule: 0; Withholding period: ; Host/pest details: CATTLE: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, VACCINE]; SHEEP: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, VACCINE]; SHEEP RAM (MALE): [SWELLED HEAD]; For the prevention of enterotoxaemia (pulpy kidney disease), tetanus, black disease, malignant oedema (blackleg like disease) and blackleg in cattle and sheep, including swelled head in rams.
Authorization status:
Registered
Authorization number:
51279
Authorization date:
2019-07-01

APPENDIX2

Australian Government

Australian Pesticides

Veterinary Medicines Authority

TEMPLATE FOR RELEVANT LABEL PARTICULARS (RLPs)

(Veterinary Products)

Select appropriate:

New Product (include

applicable RLPs)

Variation

(highlight instructions that

being varied).

Approval

of label

being

varied:

51279/1 [2,3.4]10509

Signal heading:

Product name:

Active

constituent/s:

Statement of

claims:

Net contents:

Directions for Use

Heading:

Restraints:

Contraindications:

Precautions:

Side effects:

Dosage

&

administration:

FOR ANIMAL TREATMENT ONLY

Ultravac® 5

1 Vaccine

Ultravac 5in1 is a multicomponent adjuvanted product containing

Clostridium

perfringens

typeD<:

51U/mL

tetani

<:

2.51U/mL,

novyi

type B

<:3.51U/mL,

septicum

<:2.51U/mL

ultrafiltered toxoids)

chauvoei

0.3mL/mL

(as formol culture). The adjuvant, which

aluminium salt, increases the

level and duration of the immunity conferred

vaccine. The type of

adjuvant

the purification procedures used ensure maximum protection of

stock with minimum risk of local reactions at the site of injection. Thiomersal

mg/mL

added

a preservative.

prevention

enterotoxaemia

(pulpy

kidney disease),

tetanus,

black

disease,

malignant

oedema (blackleg-like disease) and

blackleg

cattle and sheep

including

swelled head in rams

50mL, 100mL, 250

DIRECTIONS FOR USE

READ ENCLOSED LEAFLET BEFORE USING THIS PRODUCT

Contents must

left

outer package until immediately before

use.

A,.,,.HV

Shake

well

before use and keep

thoroughly

mixed

during

use.

is important that the vaccine is kept properly mixed before and during use.

Before vaccine

injected, the proposed site of inoculation

the animal's

skin may

cleaned

swabbing with cotton-wool soaked

antiseptic

solution, such

methylated spirits.

Localised swelling may develop at the site of injection

a firm nodular lump

persist for some weeks or even months.

route

inoculation

subcutaneous

Uust

under

skin).

recommended site for injection

high

neck, behind the ear.

Cattle

sheep

vaccinated

age.

Lambs

most

conveniently

vaccinated

marking

time,

calves

from

six weeks

onwards.

18 Wormald Street, Symonston ACT 2609

PO Box 6182, Kingston ACT 2604 Australia

Tel:

2 6210 4700 Fax:

2 6210 4874

www.apvma.gov.au ABN 19 495 043 447

<CU

Give

two

doses

of

vaccine

for

protective

immunity.

The

second

dose

is

given

4

to

6

weeks

after

the

first,

for

long

lasting

protection.

A

booster

dose

every

12

months

is

required

to

maintain

the

protective

level

of

immunity.

Level

of

Protective

Level

1

?

-:t

4

~=;.

7

Q

1n

11

1?

booster

Cattle, including calves:

followed by a second dose

four

weeks later.

Sheep, including lambs:

followed

a second dose of 1

four

weeks later.

Young lambs may

vaccinated whilst being held during marking operations.

Older sheep,

including

pregnant ewes,

most conveniently vaccinated

while they are standing

a race.

A.

Single Doses

Single doses of the vaccine may be withdrawn from the pack using a sterilized

hypodermic needle and syringe after disinfecting the stopper of the vaccine

pack.

B. Use with Automatic Vaccinator

An automatic vaccinator may be attached to the pack

follows:

Remove the sterilized plastic cap and tube from the pack

Connect the tube to the automatic vaccinator

Disinfect the stopper with a suitable antiseptic,

e.g.

methylated spirits

Screw the

to the plastic bottle of the vaccine which will cause the

needle to penetrate the stopper

Prime the automatic vaccinator by depressing the plunger several times

and vaccine will flow to the needle

NOTE: Before attachment, used automatic vaccinators should be re-sterilized

by taking apart and boiling for at least ten minutes.

careful not to contaminate the vaccinator during re-assembly.

Store unused material upright, at

2·c

a·c

(refrigerated) and

the original

cardboard packaging to protect from light.

18 Wormald Street, Symonston ACT 2609

PO Box 6182, Kingston

2604 Australia

Tel:

2 6210 4700 Fax:

2 6210 4874

www.apvma.gov.au

19 495 043 447

General

directions:

VACCINATION PROGRAMMES

Cattle:

A booster dose of 2 mL given 12 months after the two basic doses of

vaccine should

confer lifelong immunity against tetanus and

blackleg. To

maintain effective immunity against black disease, annual booster doses of

Ultravac 5in1

should

given.

The two

basic doses of

Ultravac 5in1

should

provide

effective immunity

against

enterotoxaemia

three

months.

Booster

doses

therefore

necessary to maintain immunity against enterotoxaemia

cattle and should

given at appropriate intervals according to local and seasonal conditions.

Sheep:

A booster dose of 1

given 12 months after the two basic doses of

vaccine should confer lifelong immunity against tetanus and blackleg, but may

not do

against enterotoxaemia (pulpy kidney disease) or black disease.

Further annual doses may

required to maintain effective immunity against

these diseases

areas where the risks from the disease are known to

high.

Pregnant ewes: If the ewes have not been previously vaccinated, a 1 mL

dose should

given at the time of mating and a second dose of 1 mL should

given within four weeks of the expected date of lambing. If the ewes have

been previously vaccinated, the dose at the time of mating may be omitted.

Successfully vaccinated pregnant ewes will not only be protected themselves

but will also pass

immunity to their lambs

the colostrum or 'first milk';

such lambs should be protected for the first 6 to 8 weeks of their lives against

these diseases.

DEVELOPMENT OF IMMUNITY

Immunity develops about 10 days after vaccination. The second dose, given

four weeks after the first should ensure a high level of immunity against the

diseases covered by the vaccine.

INDICATIONS

FOR

USE

Ultravac 5in1

is effective

the prevention of enterotoxaemia (pulpy kidney

disease), tetanus, black disease, blackleg and malignant oedema (blackleg-

like disease)

cattle and sheep including swelled head

rams.

Black disease occurs

a sequel to liver fluke infestation and deaths can

result from this cause also.

Ultravac 5in1

to prevent black disease

does not protect against losses caused by liver fluke.

If unexpected losses of animals have occurred, stockowners should consult

their veterinarian

order to ensure that a correct diagnosis

made and the

most effective vaccination programme instituted.

18 Wormald Street, Symonston

2609

PO Box 6182, Kingston

2604 Australia

Tel:

2 6210 4700 Fax:

2 6210 4874

www.apvma.gov.au ABN 19 495 043 447

USE OF TETANUS ANTITOXIN

If immediate short-term

protection

required

counter

outbreak

tetanus,

Tetanus antitoxin should

used (see "Tetanus Antitoxin" leaflet).

Although

antitoxin

useful

controlling

outbreaks

of tetanus,

usefulness is limited owing to the shortness of its protective action.

The vaccine has been fully tested and found to conform to accepted

standards of potency, safety and sterility.

CAUTION AVOID CARCASE DAMAGE

Sterilise all injection apparatus by boiling

water for 10 minutes (or

equivalent) before use.

Avoid use

strong disinfectants

apparatus.

Maintain cleanliness at

times during vaccination.

Great care must

taken to avoid contamination

the vaccine, needle

internal parts of

the syringe

contact with unsterile surfaces or unwashed hands.

Keep needles sharp and clean. Replace frequently.

Use the shortest possible needle, not exceeding

length.

As far as possible avoid injection

animals during wet weather or under

dusty conditions. Animals should preferably be inoculated

temporary

yards on clean grass,

shearing sheds

fixed mustering yards are

likely to

heavily contaminated with clostridial spores.

This product must

injected only under the skin (subcutaneously).

If possible inject high on the neck behind the ear, i.e. under the skin

the side

the neck

Oust

behind and below the base of the ear).

inject at any other site.

This

product

can

be stored

and

used

for

up

to

30

days

after first

opening.

On

each subsequent reuse, swab the opening with a suitable

disinfectant (for example,

methylated

spirits)

both

before

and

after

using.

A sterile needle and syringe must

be

used each time product

is

removed.

When not

in

use during any given vaccination session, keep the vaccine

out of direct sunlight and as cool

as

possible.

Do

not leave exposed to

light or at high temperatures for long periods.

Ideally, place the vaccine

pack into this original cardboard carton and place

in

either

an

esky with

an

icebrick or

in

a refrigerator.

RESEALING

A partially used pack can be stored and used for

to 30 days after first

opening if the following steps are taken:

Unscrew the delivery tube from the vaccine pack

Empty the delivery tube and vaccinator by depressing the plunger several

times

Disinfect the stopper with a suitable antiseptic,

e.g.

methylated spirits

18

Wormald

Street,

Symonston

ACT 2609

PO Box 6182. Kingston

2604 Australia

Tel:

2 6210 4700

Fax:

2 6210 4874

www.apvma.gov.au

ABN

19

495 043 447

Withholding

Period/s:

Trade Advice:

Safety Directions:

First Aid:

Additional

user

safety:

Environmental

statements:

Disposal:

Storage:

Name & address:

Place the vaccine pack in the original outer packaging

store

upright

refrigerator. Do not freeze.

Before re-use, the delivery tube and cap should be sterilised by boiling

least ten minutes.

NOTE:

plastic delivery tube may become opaque

Frequent attachment

the connecting tube

cause the stopper to leak.

Therefore, the

tube

should not be attached more than twice

This pack

compatible with the Zoetis Quickshot Vaccinator

DATE FIRST OPENED .......................

NOTE

Ultravac 5in1

has been fully tested for sterility and safety before issue, but it

must be stressed that correct vaccination procedure

the field is

equally

important

secondary

infection

prevented.

Very

occasionally,

pathogenic organisms lying dormant

the animal's tissues are activated at

the time

vaccination. This

lead to losses

stock,

fortunately is

rare

occurrence.

above

factors

beyond

control

manufacturer Zoetis cannot accept responsibility for any disability or loss

stock following vaccination.

Meat: Zero (0) days; MILK: Zero (0) days

TRADE

ADVICE:

EXPORT

SLAUGHTER INTERVAL (ESI): ESI not applicable

poisoning occurs, contact a doctor or Poisons Information Centre.

Phone

Australia 13 1126.

This material

cause a mild allergic reaction

sensitive individuals on

skin

contact.

Avoid

skin

contact.

If skin

or hair contact

occurs,

remove

contaminated clothing and flush skin and hair with running water. If splashed

eyes, wash

immediately with water.

Take care to avoid accidental self-injection.

In the event of self-administration, seek medical attention if you are concerned

show

the package leaflet or the label, to the Medical Practitioner.

Dispose

empty containers by wrapping in paper and putting

garbage.

Discarded

needles

should

immediately

placed

designated

appropriately labelled "sharps" container.

Store between 2°C and 8°C (Refrigerate. Do not freeze). Protect from light.

Zoetis Australia Pty Ltd

18

Wormald

Street,

Symonston

ACT

2609

PO Box 6182, Kingston

2604 Australia

Tel:

2 6210 4700

Fax:

2 6210 4874

www.apvma.gov.au ABN

495 043 447

38-42 Wharf Road West Ryde NSW 2114 AUSTRALIA

Australian Technical Services Toll Free 1800 814

883.

www.zoetis.com.au

The following is for APVMA use only:

APVMA

approval

APVMA No: 51279/60294

18 Wormald Street, Symonston ACT 2609

PO Box 6182, Kingston

2604 Australia

Tel:

2 6210 4700 Fax:

2 6210 4874

www.apvma.gov.au ABN

495 043 447

Product Name: Ultravac

®

5 in 1 Vaccine

Page: 1 of 5

This revision issued: April, 2010

MATERIAL SAFETY DATA SHEET

Issued by: Pfizer Australia Pty Ltd

Phone: (02)9850 3333

Section 1 - Identification of Chemical Product and Company

Pfizer Australia Pty Ltd

38-42 Wharf Road

West Ryde NSW 2114

Tel: (02) 9850 3333

Fax: (02) 9850 3399

____________________________________

Pfizer Australia Pty Ltd

A.B.N. 50 008 422 348

Substance:

Water solution/suspension of bacterial toxoids.

Trade Name:

ULTRAVAC

®

5 IN 1 VACCINE

Other Names:

Cl. perfringens Type D, Cl. tetani, Cl. septicum, Cl. novyi Type B, Cl. chauvoei

Vaccine

Pfizer MSDS Code:

0711

Product Use:

For the prevention of clostridial diseases in sheep and cattle.

Creation Date:

December, 2004

This version issued:

April, 2010

and is valid for 5 years from this date.

Section 2 - Hazards Identification

Statement of Hazardous Nature

This product is classified as:

Not classified as hazardous according to the criteria of SWA Australia.

Not a Dangerous Good according to the Australian Dangerous Goods (ADG) Code.

Risk Phrases:

Not Hazardous - No criteria found.

Safety Phrases:

Not Hazardous - No criteria found.

SUSDP Classification:

None (Aust); S2 (NZ)

ADG Classification:

None allocated. Not a Dangerous Good.

UN Number:

None allocated

E

E

E

m

m

m

e

e

e

r

r

r

g

g

g

e

e

e

n

n

n

c

c

c

y

y

y

O

O

O

v

v

v

e

e

e

r

r

r

v

v

v

i

i

i

e

e

e

w

w

w

Physical Description & colour

: Aqueous suspension.

Odour:

No data.

Major Health Hazards:

no significant risk factors have been found for this product.

P

P

P

o

o

o

t

t

t

e

e

e

n

n

n

t

t

t

i

i

i

a

a

a

l

l

l

H

H

H

e

e

e

a

a

a

l

l

l

t

t

t

h

h

h

E

E

E

f

f

f

f

f

f

e

e

e

c

c

c

t

t

t

s

s

s

Inactivated cultures and toxoids are not regarded as pathogenic in humans.

Inhalation

Short term exposure:

Significant inhalation exposure is considered to be unlikely. The spray mist may be

discomforting to the upper respiratory tract and lungs, and repeated exposure may cause sensitisation and/or

allergic/asthma-like response.

Long Term exposure:

No data for health effects associated with long term inhalation.

Skin Contact:

Short term exposure:

Available data indicates that this product is not harmful. It should present no hazards in

normal use. However product may be mildly irritating, but is unlikely to cause anything more than mild discomfort

which should disappear once contact ceases.

Long Term exposure:

No data for health effects associated with long term skin exposure.

Eye Contact:

Short term exposure

: Exposure via eyes is considered to be unlikely. This product may be mildly irritating to eyes,

but is unlikely to cause anything more than mild discomfort which should disappear once product is removed.

Long Term exposure

: No data for health effects associated with long term eye exposure.

Ingestion:

Short term exposure

: Significant oral exposure is considered to be unlikely. This product is unlikely to cause any

irritation problems in the short or long term.

Long Term exposure

: No data for health effects associated with long term ingestion.

Product Name: Ultravac

®

5 in 1 Vaccine

Page: 2 of 5

This revision issued: April, 2010

MATERIAL SAFETY DATA SHEET

Issued by: Pfizer Australia Pty Ltd

Phone: (02)9850 3333

Carcinogen Status:

SWA:

No significant ingredient is classified as carcinogenic by SWA.

NTP:

No significant ingredient is classified as carcinogenic by NTP.

IARC:

No significant ingredient is classified as carcinogenic by IARC.

Section 3 - Composition/Information on Ingredients

Ingredients

CAS No

Conc,%

TWA (mg/m

STEL (mg/m

Saline suspension *

>90

not set

not set

Adjuvant

<0.4

not set

not set

Thiomersal

54-64-8

0.01

not set

not set

Containing ultrafiltered,

Cl. perfringens Type D Toxoid ,

Cl. tetani Toxoid

Cl. novyi Type B Toxoid

Cl. septicum Toxoid

And formol culture of Cl. chauvoei

(in amounts sufficient in balanced proportion to satisfy potency requirements of BP(Vet) 1993)

This is a commercial product whose exact ratio of components may vary slightly. Minor quantities of other non

hazardous ingredients are also possible.

The TWA exposure value is the average airborne concentration of a particular substance when calculated over a normal 8 hour working day for a 5

day working week. The STEL (Short Term Exposure Limit) is an exposure value that should not be exceeded for more than 15 minutes and should

not be repeated for more than 4 times per day. There should be at least 60 minutes between successive exposures at the STEL. The term "peak "is

used when the TWA limit, because of the rapid action of the substance, should never be exceeded, even briefly.

Section 4 - First Aid Measures

General Information:

You should call The Poisons Information Centre if you feel that you may have been poisoned, burned or irritated by

this product. The number is 13 1126 from anywhere in Australia (0800 764 766 in New Zealand) and is available at all

times. Have this MSDS with you when you call.

Self Injection: Accidental self injection may lead to an inflammatory response. Medical advice should be sought on

the management of deep injections, particularly those near a joint or associated with bruising. If possible the

application of gentle squeezing pressure with absorbent material (e.g. facial tissues) at the injection site will swab up

unabsorbed vaccine. Strong squeezing of the site should be avoided. The damaged area should be thoroughly

cleansed and a topical antiseptic applied.

Inhalation:

First aid is not generally required. If in doubt, contact a Poisons Information Centre or a doctor.

Skin Contact:

Irritation is unlikely. However, if irritation does occur, flush with lukewarm, gently flowing water for 5

minutes or until chemical is removed. If in doubt obtain medical advice.

Eye Contact:

No effects expected. If irritation does occur, flush contaminated eye(s) with lukewarm, gently flowing

water for 5 minutes or until the product is removed. Obtain medical advice if irritation becomes painful or lasts more

than a few minutes.

Ingestion:

If product is swallowed or gets in mouth, wash mouth with water and give some water to drink. If

symptoms develop, or if in doubt contact a Poisons Information Centre or a doctor.

Section 5 - Fire Fighting Measures

Fire and Explosion Hazards

: There is no risk of an explosion from this product under normal circumstances if it is

involved in a fire.

Only small quantities of decomposition products are expected from this products at temperatures normally achieved in

a fire. This will only occur after heating to dryness.

Fire decomposition products from this product may be toxic if inhaled. Take appropriate protective measures.

Extinguishing Media

: Not Combustible. Use extinguishing media suited to burning materials.

Fire Fighting

: When fighting fires involving significant quantities of this product, no special equipment is believed to

be necessary.

Flash point

:

Does not burn.

Upper Flammability Limit:

Does not burn.

Lower Flammability Limit:

Does not burn.

Autoignition temperature:

Not applicable - does not burn.

Flammability Class:

Does not burn.

Product Name: Ultravac

®

5 in 1 Vaccine

Page: 3 of 5

This revision issued: April, 2010

MATERIAL SAFETY DATA SHEET

Issued by: Pfizer Australia Pty Ltd

Phone: (02)9850 3333

Section 6 - Accidental Release Measures

Minor Spills:

1. Clean up all spills immediately.

2. Avoid contact with skin and eyes.

3. Wear impervious gloves and safety glasses.

4. Place spilled material in clean, dry, sealable, labelled container. Wash spill area with large quantities of water.

Major Spills:

Not applicable.

Disposal:

1. Dilute with water and flush to sewer.

2. Decontaminate empty containers with water.

3. Recycle containers if possible, or dispose of in authorised landfill. Used needles should immediately be placed in a

designated and appropriately labelled "sharps" container.

May be disposed of in accordance with any label recommendations provided by the manufacturer.

Section 7 - Handling and Storage

Handling

: Keep exposure to this product to a minimum, and minimise the quantities kept in work areas. Check

Section 8 of this MSDS for details of personal protective measures, and make sure that those measures are followed.

The measures detailed below under "Storage" should be followed during handling in order to minimise risks to

persons using the product in the workplace. Also, avoid contact or contamination of product with incompatible

materials listed in Section 10.

Storage

: Store at 2-8°C (refrigerate). Do not freeze. Protect from light.

1. Store in original containers.

2. Keep containers securely sealed.

3. Store in a cool, dry, well-ventilated area.

4. Store away from incompatible materials and foodstuff containers.

5. Protect containers against physical damage and check regularly for leaks.

6. Observe manufacturer's storage and handling recommendations.

Make sure that the product does not come into contact with substances listed under "Materials to avoid" in Section 10.

Check packaging - there may be further storage instructions on the label.

Section 8 - Exposure Controls and Personal Protection

The following Australian Standards will provide general advice regarding safety clothing and equipment:

Respiratory equipment: AS/NZS 1715, Protective Gloves: AS 2161, Industrial Clothing: AS2919, Industrial Eye

Protection: AS1336 and AS/NZS 1337, Occupational Protective Footwear: AS/NZS2210.

SWA Exposure Limits

TWA (mg/m

3

)

STEL (mg/m

3

)

Exposure limits have not been established by SWA for any of the significant ingredients in this product.

No special equipment is usually needed when occasionally handling small quantities. The following instructions are

for bulk handling or where regular exposure in an occupational setting occurs without proper containment systems.

Ventilation:

No special ventilation requirements are normally necessary for this product. However make sure that

the work environment remains clean and that dusts are minimised.

Eye Protection:

Eye protection is not normally necessary when this product is being used. However, if in doubt,

wear suitable protective glasses or goggles.

Skin Protection:

The information at hand indicates that this product is not harmful and that normally no special skin

protection is necessary. However, we suggest that you routinely avoid contact with all chemical products and that you

wear suitable gloves (preferably elbow-length) when skin contact is likely.

Protective Material Types:

There is no specific recommendation for any particular protective material type.

Respirator:

If there is a significant chance that dusts are likely to build up in the area where this product is being

used, we recommend that you use a suitable Dust Mask.

Section 9 - Physical and Chemical Properties:

Physical Description & colour

Aqueous suspension.

Odour:

No data.

Boiling Point:

Approximately 100°C at 100kPa.

Freezing/Melting Point:

Approximately 0°C.

Volatiles:

Water component.

Vapour Pressure:

2.37 kPa at 20°C (water vapour pressure).

Vapour Density:

No data.

Product Name: Ultravac

®

5 in 1 Vaccine

Page: 4 of 5

This revision issued: April, 2010

MATERIAL SAFETY DATA SHEET

Issued by: Pfizer Australia Pty Ltd

Phone: (02)9850 3333

Specific Gravity:

1.01

Water Solubility:

Completely soluble in water.

pH:

No data.

Volatility:

No data.

Odour Threshold:

No data.

Evaporation Rate:

No data.

Coeff Oil/water distribution

No data

Autoignition temp:

Not applicable - does not burn.

Section 10 - Stability and Reactivity

Reactivity:

This product is unlikely to react or decompose under normal storage conditions. However, if you have

any doubts, contact the supplier for advice on shelf life properties.

Conditions to Avoid:

Store in the closed original container in a dry, cool, well-ventilated area out of direct sunlight.

Incompatibilities:

strong acids, strong bases, strong oxidising agents.

Fire Decomposition:

No specific data. Based on composition of proteins and fats, the following might be expected:

Carbon dioxide, and if combustion is incomplete, carbon monoxide and smoke. Nitrogen and its compounds, and

under some circumstances, oxides of nitrogen. Oxides of sulfur (sulfur dioxide is a respiratory hazard) and other sulfur

compounds. Water.

Polymerisation:

This product will not undergo polymerisation reactions.

Section 11 - Toxicological Information

Target Organs:

There is no data to hand indicating any particular target organs.

C

C

C

l

l

l

a

a

a

s

s

s

s

s

s

i

i

i

f

f

f

i

i

i

c

c

c

a

a

a

t

t

t

i

i

i

o

o

o

n

n

n

o

o

o

f

f

f

H

H

H

a

a

a

z

z

z

a

a

a

r

r

r

d

d

d

o

o

o

u

u

u

s

s

s

I

I

I

n

n

n

g

g

g

r

r

r

e

e

e

d

d

d

i

i

i

e

e

e

n

n

n

t

t

t

s

s

s

Ingredient

Risk Phrases

No ingredient mentioned in the HSIS database is present in this product at hazardous concentrations.

Section 12 - Ecological Information

This product is biodegradable. It will not accumulate in the soil or water or cause long term problems.

Section 13 - Disposal Considerations

Disposal:

Instructions concerning the disposal of this product and its containers are given on the product label.

These should be carefully followed.

Section 14 - Transport Information

ADG Code:

This product is not classified as a Dangerous Good. No special transport conditions are necessary

unless required by other regulations.

Section 15 - Regulatory Information

AICS:

All of the significant ingredients in this formulation are to be found in the public AICS Database.

Section 16 - Other Information

This MSDS contains only safety-related information. For other data see product literature.

Acronyms:

ADG Code

Australian Code for the Transport of Dangerous Goods by Road and Rail, 7th Edition

AICS

Australian Inventory of Chemical Substances

CAS number

Chemical Abstracts Service Registry Number

Hazchem Number

Emergency action code of numbers and letters that provide information to emergency

services especially firefighters

IARC

International Agency for Research on Cancer

SWA

Safe Work Australia, formerly ASCC and NOHSC

NOS

Not otherwise specified

NTP

National Toxicology Program (USA)

R-Phrase

Risk Phrase

SUSDP

Standard for the Uniform Scheduling of Drugs & Poisons

UN Number

United Nations Number

Product Name: Ultravac

®

5 in 1 Vaccine

Page: 5 of 5

This revision issued: April, 2010

MATERIAL SAFETY DATA SHEET

Issued by: Pfizer Australia Pty Ltd

Phone: (02)9850 3333

Contact Points:

Pfizer

(02)9850 3333 (Business hours)

Ask for Environmental Health & Safety Manager

Police and Fire Brigade:

Dial 000

If ineffective:

Dial Poisons Information Centre

(

13 1126 from anywhere in Australia)

Please read all labels carefully before using product.

This MSDS copyright © Kilford & Kilford Pty Ltd, April, 2010.

http://www.kilford.com.au/ Phone (02)9251 4532

Similar products

Search alerts related to this product

View documents history

Share this information